Medicon Valley Alliance strengthens its Board of Directors

The Board of Directors of Medicon Valley Alliance (MVA), the Danish-Swedish life science cluster organization, have welcomed new members.

At the Ordinary General Meeting, Thursday 16th of April, which was organized as an online meeting, the MVA Board of Directors welcomed Linn Mandahl, General Manager at AbbVie Scandinavia, as a new board member.

“It is an honor and a privilege to be selected to the MVA Board and when we see the tremendous challenges that the healthcare is facing, not least due to COVID-19, it is clear that increased cooperation between sectors and across borders will be crucial in the future. With MVA as a bridge-builder between Swedish and Danish companies, regions and universities the life science sector in Greater Copenhagen is strengthened and as a CEO of a Scandinavian subsidiary, collaboration across the borders is essential. I am very impressed by the work that MVA is doing and I look forward to contribute to the journey towards our common goal,” says Linn Mandahl, General Manager, AbbVie Scandinavia.

Linn Mandahl. Photo: AbbVie Scandinavia

In addition, Malmö University, upgraded its membership and will in the future have a permanent seat in the board along with the representatives from University of Copenhagen and Lund University.

“I see great opportunities for the future. It concerns everything, from common research and development efforts to increased opportunities for international financing,” says Thomas Arnebrant, Professor and adviser to the vice-chancellor at Malmö University.

Thomas Arnebrant. Photo: Malmö University

Also, Chairman, Søren Bregenholt (CEO, Macrophage Pharma) and vice chairman, Ulf Andersson, (CEO Medeon Science Park) were both reelected.

An all time high of more than 300 members

With more than 50 new member companies and organizations having joined MVA during 2019, the organization has now reached an all time high of more than 300 members, states MVA.

“We are on the right track, we have initiated strategic collaboration projects within for instance diabetes and microbiome worth more than 14 million € and we experience a growing interest in MVA events and activities. This gives us good reason for optimism, and as soon as the situation normalizes somewhat, I am sure we will be well-positioned to continue our efforts to develop and promote the cluster even further. It is still our explicit ambition to make Medicon Valley the strongest life science cluster in Northern Europe,” says Petter Hartman, CEO of MVA.

Photo of Petter Hartman (above): Tove Smeds